TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21613350
Drug: 7-h GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-h GH infusion (0.2-0.3 mg in total) that terminated 5 h before the clamp (study 1)
Study: 21613350
Drug: 7-h GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-h GH infusion timed to continue during the first hour of the clamp (study 2)
Study: 19357559
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab injection after cataract surgery
Study: 19357559
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution injection (Control)
Study: 11707669
Drug: Tenofovir DF
Normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir DF plus Hydroxyurea (500 mg bid for 28 days)
Study: 11707669
Drug: Tenofovir DF
Normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir DF (75 mg once daily for 28 days)
Study: 3537092
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Theophylline and Albuterol
Study: 27776678
Drug: PM plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM plus cognitive behavioral therapy (CBT)
Study: 23789813
Drug: Bolus saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus saline injection with arm elevation
Study: 8342756
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no saline injection)
Study: 16774830
Drug: Intrathecal hyperbaric
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal hyperbaric bupivacaine 3.75 mg
Study: 19843797
Drug: Intrathecal hyperbaric
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal hyperbaric bupivacaine 9 mg
Study: 11206018
Drug: Conservative (ischemia-guided)
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative (ischemia-guided) strategy with aggressive medical therapy
Study: 11206018
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (intensive antiplatelet, antithrombotic, and anti-ischemic therapy)
Study: 8632538
Drug: 1 instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 instillation of mitomycin C (40 mg/40 ml water)
Study: 8632538
Drug: 5 instillations
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 instillations of mitomycin C (40 mg/40 ml water)
Study: 2860183
Drug: Topical povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical povidone-iodine (PVP-I)
Study: 20436703
Drug: Tandem high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandem high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR)
Study: 20436703
Drug: Single high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR)
Study: 17708780
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS over left dorsolateral prefrontal cortex (DLPFC) (5 Hz rTMS; 120% motor threshold) with placebo pill
Study: 17708780
Drug: Sham rTMS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham rTMS with fluoxetine 20 mg/d
Study: 7104176
Drug: Spironolactone 50
Normalized name: spironolactone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 50 mg daily
Study: 9431896
Drug: alpha‐IFN 2a,
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐IFN 2a, 3 MU, three times weekly for 12 months
Study: 2948451
Drug: Etretin therapy
Normalized name: etretinate
DrugBank: Etretinate (DB00926)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etretin therapy (50 mg/d)
Study: 2948451
Drug: Etretin therapy
Normalized name: etretinate
DrugBank: Etretinate (DB00926)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etretin therapy
Study: 2948451
Drug: Etretin therapy
Normalized name: etretinate
DrugBank: Etretinate (DB00926)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etretin therapy for six or more months
Study: 15283938
Drug: Oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormone replacement therapy (0.625 mg conjugated equine estrogens + 5 mg medroxyprogesterone daily)
Study: 15283938
Drug: Transdermal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormone replacement therapy (50 microg estradiol + 5 mg medroxyprogesterone daily)
Study: 15283938
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Tibolone and both hormone replacement therapies)
Study: 11828945
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2 and Carboplatin AUC 7
Study: 11828945
Drug: Paclitaxel 160
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 160 mg/m2 and Carboplatin AUC 6
Study: 11828945
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2 and Carboplatin AUC 6
Study: 3033389
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg bid for 8 days on a 50 mmol sodium diet
Study: 3033389
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg bid for 8 days on a 200 mmol sodium diet
Study: 18575157
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg, 40 mg-80 mg)
Study: 9848888
Drug: Cilostazol 100
Normalized name: cilostazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 100 mg BID for 12 weeks
Study: 8923572
Drug: 0.56 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.56 g/kg alcohol
Study: 3180108
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg dexfenfluramine (d‐FF)
Study: 3180108
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg metergoline (MTG)
Study: 20609970
Drug: Prandial Technosphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prandial Technosphere inhaled insulin plus bedtime insulin glargine
Study: 20609970
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily premixed biaspart insulin
Study: 16488299
Drug: ISA247 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISA247 0.5 mg/kg/d
Study: 16488299
Drug: ISA247 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISA247 1.5 mg/kg/d
Study: 8607952
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 0.25% bupivacaine hydrochloride infiltrated around each tonsil
Study: 1333934
Drug: Sumatriptan (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (8 mg)
Study: 1333934
Drug: Sumatriptan (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (16 mg)
Study: 1333934
Drug: Morphine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (20 mg)
Study: 6365107
Drug: Pantethine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantethine (300 mg t.i.d.) in type IIB patients
Study: 6365107
Drug: Pantethine (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantethine (first treatment) in type IIB patients
Study: 6365107
Drug: Pantethine (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantethine (first treatment) in type IV patients
Study: 30794649
Drug: Women taking
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women taking oral contraceptives
Study: 30794649
Drug: Women not
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women not taking oral contraceptives
Study: 29194198
Drug: Latanoprostene bunod
Normalized name: Latanoprostene bunod
DrugBank: Latanoprostene bunod (DB11660)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Latanoprostene bunod (LBN) 0.024% once daily (qd)
Study: 29194198
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate 0.5% twice daily (bid)
Study: 26707996
Drug: Letrozole 10
Normalized name: letrozole 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 10 mg daily for 7 days
Study: 25163399
Drug: Oral polio
Normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral polio vaccine (OPV0)
Study: 21801101
Drug: Autologous whole
Normalized name: Autologous whole blood product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous whole blood (AWB) injections
Study: 21801101
Drug: Autologous serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous serum (AS) injections
Study: 19919597
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual with Assessment (TAU+)
Study: 15661431
Drug: Ketamine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (60 and 120 ng/mL)
Study: 11757473
Drug: Sustained-release isosorbide-5-mononitrate
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release isosorbide-5-mononitrate (IS-5-MN) 100 mg/day
Study: 9404745
Drug: Placebo MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo MDI through a 750‐mL cone‐shaped spacer (2 puffs) and nebulized salbutamol aerosol 0.5 mL in 1.5 mL saline solution (group 1, n=25)
Study: 9404745
Drug: Salbutamol MDI
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol MDI and 0.5 mL saline solution in 1.5 mL saline solution (group 2, n=25)
Study: 2826548
Drug: Keyes' method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keyes' method of non‐surgical therapy
Study: 25979532
Drug: Chest tube
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest tube removal at drainage volume of less than 300 ml/day (Group B)
Study: 25979532
Drug: Chest tube
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest tube removal at drainage volume of less than 450 ml/day (Group C)
Study: 25979532
Drug: Chest tube
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest tube removal at drainage volume of 150 ml/day or less (Group A)
Study: 11394950
Drug: Worksite physical
Normalized name: Workvie
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Worksite physical exercise intervention (9 months, supervised, twice a week)
Study: 8354136
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg ticlopidine twice daily (group 1)
Study: 8354136
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg aspirin daily (group 2)
Study: 31883526
Drug: 12 weekly
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weekly sessions of non-specialist-delivered Interpersonal Psychotherapy (IPT)
Study: 31883526
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of fluoxetine prescribed by a nurse or clinical officer
Study: 31883526
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (IPT and fluoxetine)
Study: 26311640
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol 400 µg every 6 hours for a maximum of 4 doses after 200 mg oral mifepristone
Study: 26311640
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 400 µg every 3 hours for a maximum of 4 doses after 200 mg oral mifepristone
Study: 21375163
Drug: Conventional phacoemulsification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional phacoemulsification with dual infusion technique through irrigating chopper
Study: 15259288
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen plus medroxyprogesterone acetate (CE/MPA 0.625 mg/5 mg)
Study: 15259288
Drug: 17beta‐estradiol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta‐estradiol plus norethisterone acetate (E2/NETA 2 mg/1 mg)
Study: 15259288
Drug: CE/MPA 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE/MPA 0.625 mg/5 mg
Study: 11334726
Drug: Oxaliplatin 85
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85 mg/m(2) every 2 weeks
Study: 11334726
Drug: Oxaliplatin combined
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin combined with 5-FU 425 mg/m(2)/day and FA 20 mg/m(2)/dayx5 days every 4 weeks
Study: 9234925
Drug: Cyclophosphamide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 600 mg/m2 plus carboplatin 350 mg/m2
Study: 9234925
Drug: Cyclophosphamide 1000
Normalized name: cyclophosphamide 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 1000 mg/m2 plus cisplatin 80 mg/m2
Study: 2445151
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg nickel (nickel sulphate)
Study: 2445151
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg cobalt (cobalt sulphate)
Study: 30993587
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (BV) at doses of 1.8 or 2.4 mg/kg once every three weeks
Study: 28042070
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (FEC100→taxane) ± bevacizumab
Study: 25867783
Drug: Daily smartphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily smartphone self-monitoring (n = 34)
Study: 23713407
Drug: Slow-release triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release triamcinolone and lidocain injection
Study: 23713407
Drug: Saline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline and lidocain injection
Study: 21475252
Drug: LDAC +
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDAC + ATO (0.25 mg/kg on days 1-5, 9, and 11 for at least four courses every 4 to 6 weeks)
Study: 21475252
Drug: LDAC (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDAC (20 mg b.d. for 10 days)
Study: 18641209
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (100 mg L-theanine + 50 mg caffeine)
Study: 18641209
Drug: Caffeine alone
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine alone (50 mg)
Study: 18641209
Drug: L-theanine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-theanine alone (100 mg)
Study: 12915959
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium skimmed milk (50 g daily, containing 1200 mg calcium)
Study: 1474173
Drug: dimenhydrinate, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: dimenhydrinate, 100 mg
Study: 1474173
Drug: meclizine, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: meclizine, 50 mg
Study: 6386032
Drug: Superficial radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Superficial radiotherapy as an adjunct to topical therapy
Study: 29448833
Drug: luseogliflozin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: luseogliflozin 2.5 mg
Study: 22089958
Drug: Vibrotactile neurofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibrotactile neurofeedback training (15 min daily for 2 weeks)
Study: 20128284
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone for 4 days along with anti-inflammatory drug
Study: 20128284
Drug: Placebo along
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo along with anti-inflammatory drug
Study: 17729433
Drug: Periinterventional prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periinterventional prophylactic antibiosis (Unacid 3 g or Ciprobay 100 mg for penicillin allergy)
Study: 11729368
Drug: PEG-hirudin low
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-hirudin low dose (0.1 mg/kg bolus, 0.01 mg/kg/h infusion)
Study: 11729368
Drug: PEG-hirudin intermediate
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-hirudin intermediate dose (0.15 mg/kg and 0.015 mg/kg/h)
Study: 11729368
Drug: PEG-hirudin high
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-hirudin high dose (0.2 mg/kg and 0.02 mg/kg/h)
Study: 11729368
Drug: Heparin (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (control group)
Study: 1837646
Drug: Recombinant hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hepatitis B vaccine (GenHevac B Pasteur) 20 micrograms administered at birth, 1 month, 2 months, and booster at 12 months; in combination with 100 IU HBIg for high risk group.
Study: 1837646
Drug: Recombinant hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hepatitis B vaccine (GenHevac B Pasteur) 20 micrograms administered at birth, 1 month, 2 months, and booster at 12 months; alone for low risk group.
Study: 3063335
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous alizapride (3.5 mg/kg)
Study: 3063335
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous metoclopramide (1 mg/kg)
Study: 24944332
Drug: Dual-release hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-release hydrocortisone (DR-HC) 20-40 mg once daily
Study: 24944332
Drug: Thrice-daily hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Thrice-daily hydrocortisone 20-40 mg divided into three daily doses
Study: 24944332
Drug: Thrice-daily hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Thrice-daily hydrocortisone
Study: 20816297
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral hygiene instructions with fluoride toothpaste
Study: 18472682
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (randomized drug assignments)
Study: 12873958
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic solution with epinephrine (Group E)
Study: 12873958
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic solution without epinephrine (Group P)
Study: 1615615
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of cefadroxil once a day for three days
Study: 1615615
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of nitrofurantoin three times a day for three days
Study: 6228746
Drug: Gamma-vinyl GABA,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-vinyl GABA, 2 g/day
Study: 31780017
Drug: N. sativa
Approvals — FDA: no, EMA: no, PMDA: no
Description: N. sativa 5% gel
Study: 27436275
Drug: Exenatide QW
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide QW 2 mg (self-administered)
Study: 27436275
Drug: Exenatide QMS
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide QMS 5 mg (caregiver-administered)
Study: 27436275
Drug: Exenatide QMS
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide QMS 8 mg (caregiver-administered)
Study: 27436275
Drug: Exenatide QMS
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide QMS 11 mg (caregiver-administered)
Study: 24831438
Drug: Modified oral
Normalized name: Food Starch, Modified Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified oral food challenge with doses of roasted peanuts ranging from 3 to 4500 mg of peanut protein
Study: 24831438
Drug: Modified oral
Normalized name: Food Starch, Modified Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified oral food challenge
Study: 22383993
Drug: Daclizumab (anti-IL-2Rα
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab (anti-IL-2Rα monoclonal antibody), given during lymphodepleting temozolomide (TMZ) treatment
Study: 16143126
Drug: Selenomethionine 200
Normalized name: selenomethionine 200 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenomethionine 200 microg daily